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High-density single cell mRNA 
sequencing to characterize 
circulating tumor cells in 
hepatocellular carcinoma
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Patients with hepatocellular carcinoma (HCC) release tumor cells to the bloodstream, which can be 
detected using cell surface markers. Despite numerous reports suggest a direct correlation between 
the number of circulating tumor cells (CTCs) and poor clinical outcomes, few studies have provided a 
thorough molecular characterization of CTCs. Due to the limited access to tissue samples in patients 
at advanced stages of HCC, it is crucial to develop new technologies to identify HCC cancer drivers 
in routine clinical conditions. Here, we describe a method that sequentially combines image flow 
cytometry and high density single-cell mRNA sequencing to identify CTCs in HCC patients. Genome 
wide expression profiling of CTCs using this approach demonstrates CTC heterogeneity and helps 
detect known oncogenic drivers in HCC such as IGF2. This integrated approach provides a novel tool for 
biomarker development in HCC using liquid biopsy.
The concept of liquid biopsy, which entails the analysis of tumor components released to the bloodstream (i.e., 
DNA and tumor cells), has revolutionized oncology1. The main advantages of liquid biopsy are: (1) the technique 
is minimally invasive, which decreases the financial costs and potential complications of tissue biopsies, and (2) 
it is easy to iterate during patients’ follow-up. Both features are crucial considering how cancer cells adapt to 
pharmacological pressures, and acquire new molecular alterations not detected at baseline2. To account for this, 
we would be required to perform repeated invasive tissue biopsies upon every treatment, which is difficult to 
implement in routine clinical conditions. Thus, to develop new biomarkers using liquid biopsy strategies is imper-
ative. This is even more critical in hepatocellular carcinoma (HCC) because these patients are generally diagnosed 
using imaging techniques3, so unlike most solid tumors, access to tissue to conduct biomarker studies in HCC is 
significantly more difficult. In the United States, liver cancer (including both HCC and intrahepatic cholangiocar-
cinoma) is currently the fastest growing malignancy both in terms of incidence and mortality4.
Most of the studies exploring circulating tumor cells (CTCs) in HCC have shown a direct correlation between 
higher CTC number and poor clinical outcomes5. In most of them, CTC detection relied on the analysis of a small 
number of surface markers. Indeed, the only FDA-approved device to detect CTCs is based on the expression 
of the surface marker EPCAM. These methods do not include isolation of CTCs to conduct a higher resolution 
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molecular characterization, which is critical to use CTCs analysis as a proxy to interrogate dominant tumor 
molecular alterations. This concept was recently shown in a patient with metastatic breast cancer using whole 
genome sequencing (WGS) in CTCs6, which allowed detecting known driver mutations in the CTC compart-
ment. Similarly, WGS of CTCs isolated from a patient with metastatic prostate cancer revealed driver mutations 
which could be tracked to corresponding tumor tissue7.
There are few data on whole-genome transcriptome profiling of CTCs using single-cell technologies8. 
This was due to the relative low throughput of single-cell isolation techniques, which allowed to sequence in 
parallel relatively low numbers of cells. Considering the rarity of CTCs in the blood (estimated 0–10 CTCs 
out of 7,000,000 nucleated cells)9, extensive enrichment for CTCs was required before single-cell sequenc-
ing. Studies using scRNAseq to analyze CTCs leveraged different approaches to isolate CTCs using robotic 
or microfluidic devices10,11. CTCs isolation heavily relies on the identification of specific markers such as 
EpCAM in prostate cancer or NG2 in melanoma10,11. These studies confirm the ability of genome-wide 
expression analyses of isolated CTCs to detect de-regulation of genes found in tissue counterparts10. Other 
CTC isolation methods such as those based on cell-surface vimentin expression enabled the identification 
of PD-L1 as a prognostic marker in patients with colorectal or prostate cancer12. Alternative approaches 
favored the use of PCR-based technologies to derive CTC expression signatures analyzing a limited number 
of genes, as recently shown in HCC13. However, there is limited data on whole-genome transcriptomic profil-
ing of CTCs from HCC patients. Recent technological developments including novel single-cell technologies 
prompted us to conduct a dense transcriptomic profiling of CTCs using a sequential protocol that maximizes 
CTC detection rate. We provide the proof-of-principle to further develop single-cell sequencing for bio-
marker development in HCC.
Results
A novel pipeline to detect CTCs using whole transcriptome data. To enable the comprehen-
sive characterization of CTC transcriptome, we developed an analytical pipeline that combines Imaging Flow 
Cytometry (IFC) and Single-cell RNA sequencing (scRNA-seq). Our protocol uses 8 mL of whole blood and con-
sists of 3 sequential steps: (1) CD45 negative enrichment, (2) selection of patients using IFC, and (3) scRNAseq 
using 10X Genomics Chromium® (Fig. 1). This enables mRNA sequencing in up to 10,000 cells with a capture 
efficiency up to 65% for high-throughput expression profiling using unique molecular identifiers. Considering 
the variable range of CTCs in HCC5, our approach maximizes the odds of CTC detection. In this proof-of-prin-
ciple study, we included 6 HCC patients and 1 control subject (Table 1). Four out of the six HCC patients had 
potential CTCs on IFC, as defined by a combination of factors: CD45 negative, at least 1 positive marker among 
pan-CK, GPC3, ASGPR1, or EPCAM, and compatible shape by bright field morphologic analysis. In accordance 
with previous reports14, the control subject had no candidate CTCs. As a pilot study, once IFC selection was 
optimized, we selected two out of the four patientswith candidate CTCs, those with higher number of CD45 
negatively enriched cells, for further analysis with scRNAseq (Fig. 2A,B).
Due to the rarity of CTCs in the blood, we adjusted the analytical scRNAseq pipeline to be specifically sen-
sitive to detect outliers. We sequenced a total of 7,104 and 3,130 cells in patients 1 and 2, respectively. Median 
number of RNA molecules and genes detected per cell in patient 1 were 3,046 (range 1,004–21,169) and 1,098 
(range 202–4,109). In patient 2, we detected a median of 2,552 RNA molecules (range 1,147–27,950) and 933 
genes (range 202–4,484) per cell. We used the most variable genes to compute the main sources of variability in 
the dataset, as depicted in a principal component (PC) analysis (Fig. 2C,D). This approach identified two CTCs 
from patient 1 and one CTC from patient 2 with gene expression profiles dramatically different from the other 
clonal populations in the blood. These candidate CTCs aligned along the first PC, emphasizing the strong source 
of variation captured by this PC. In both cases, the genes that defined PC1, which captures the maximum vari-
ance, were highly weighted on liver specific genes (STable 1). As predicted, when comparing the scaled expression 
values of the 3 candidate CTCs from the 2 patients with the rest of the cells, we also found numerous liver-related 
genes among the 100 top differentially expressed genes (Fig. 3A and STable 2). These genes are involved in liver 
physiology including apolipoproteins, coagulation factors, alcohol dehydrogenases, cytochromes, etc. The 3 can-
didate CTCs isolated from both patients shared 12% of their top 100 expressed genes (TTR, FABP1, GSTA1, 
APOH, FGB, HULC, ALB, APOA2, SEPP1, APOC1, HPD and ORM1), which increased our confidence of efficient 
CTC detection. To further support a hepatic lineage of these outlier cells, we performed gene set enrichment 
analysis (GSEA) on their scaled expression as compared to all the other cells. Bile acid and xenobiotic metabolism 
were among the top positively enriched gene sets in these cells (Fig. 3B). We next sought to characterize the rest 
Figure 1. Summary of study design and sample workflow. Illustration by Jill Gregory. Printed with permission 
from Mount Sinai Health System, licensed under CC BY-ND (https://creativecommons.org/licenses/by-nd/4.0/).
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of the blood cells based on their gene expression profiles. Using the marker genes that define each of these clusters 
(Fig. 2C,D and STable 3) we identified cells compatible with monocytes, NK cells, B and T cells, plasmacytoid 
dendritic cells and red blood cells.
Patient Gender Age Etiology Cirrhosis
BCLC 
stage AFP
Albumin 
(g/dl)
Bilirubin
(mg/dl) INR
Platelet
(10E9/L)
Imagestream data
scRNAseq
CTC 
count EPCAM+ CK+ ASGPR1+ GPC3+
Patient 1 M 68 HCV Yes C 448 2.7 1.4 1 209 5 5 3 2 0 Yes
Patient 2 M 77 HCV/Alcohol Yes C 460 1.9 1.8 1.2 116 5 5 5 0 0 Yes
Patient 3 M 64 Cryptogenic No C 140 3.2 1.1 1 200 11 11 11 4 0 No
Patient 4 M 59 HCV/Alcohol Yes B 26 3.4 0.8 1 116 0 0 0 0 0 No
Patient 5 M 63 HCV No A 2 3.5 0.2 1.1 342 4 4 0 0 0 No
Patient 6 M 44 HBV Yes A 1 3.6 0.5 1.2 114 0 0 0 0 0 No
Patient 
7* F 56 — No NA NA 4.2 0.6 1 222 0 0 0 0 0 No
Table 1. Clinical characteristics and Imagestream analysis of the patients analyzed. *Subject without cancer; 
NA: Not applicable; HCV: Hepatitis C virus; HBV: Hepatitis B virus; M: Male; F: Female; AFP: Alpha-
fetoprotein; BCLC: Barcelona Clinic Liver Cancer.
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Figure 2. Identification of CTCs using single-cell RNAseq. Top panels show candidate CTCs identified by 
Imagestream in patients 1 (A) and 2 (B). (C,D) PCA plots after outlier-detection normalization for each patient, 
including the loadings for the top marker genes of PC1, and a t-SNE plot of non-CTCs cells with predicted 
clusters based on the top-ranked marker genes (RBC: red blood cells, NK: Natural Killer, DC: dendritic cells).
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As predicted, our CD45 negative selection increased the ratio of CTCs to non-CTCs up to approximately 1 
CTC per ~3,000 nucleated cells. In this context, high-density scRNA-seq is essential to accurately discriminate 
CTCs using whole transcriptome data. Unexpectedly, when we checked the expression of ASGPR1, a marker used 
to detect CTC in HCC15, we found that it was expressed in a significant proportion of non-CTCs, mainly mono-
cytes (Fig. 3C). Non-hepatic expression of ASGPR1 has been recently described16, which further underscores 
the added value of genome wide scRNAseq for accurate CTC detection. Altogether, these observations provide 
further evidence of the limitations of single (or targeted) marker approaches for CTC detection. In summary, scR-
NAseq detected cells in the blood of HCC patients with a genomic profile highly suggestive of an hepatic lineage.
scRNAseq identifies HCC driver genes and suggest molecular heterogeneity in CTCs. Single-cell 
RNAseq was very suggestive of a hepatic origin of the outlier cells, but the low-coverage and sparse nature of these 
data precluded an evaluation of unequivocally malignant traits such as somatic mutations or chromosomal aber-
rations. Sequencing depth was suboptimal to confidently call mutations in well-known HCC hotspots. However, 
in both patients, candidate CTCs expressed Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA 
(HULC), while absent in the other blood cells. HULC is a lncRNA with known oncogenic properties in HCC17. We 
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Figure 3. Characterization of CTCs and identification of potential HCC driver genes. (A) Volcano plot of 
differential gene expression between the 3 CTCs found in the 2 patients and the rest of blood cells. Red dots 
denote comparisons with an FDR < 0.05. (B) Bar size represent normalized enrichment score values and FDR 
(i.e., red gradient) for gene sets significantly enriched in each CTC resulting from GSEA. (C) Expression of 
ASGR1 on scRNAseq in non-CTC blood cells. Scaled expression depicted as a red gradient (grey denotes no 
expression detected for ASGR1).
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also detected other genes frequently up-regulated in HCC such as SPINK1, IGF2, SPP1 or BRIC5 (STable 2). This, 
added to the fact that circulating cells of hepatic lineage are neither detected in the bloodstream of healthy donors 
nor in patients with non-malignant chronic liver diseases13, supports the malignant nature of our candidate CTCs.
Despite the mutational landscape of HCC is fairly known18, the most prevalent HCC mutations are undrugga-
ble. Indeed, HCC ranks second to last in terms of number of druggable mutations19, which emphasizes the need 
to develop new approaches to detect druggable events in HCC patients. Among the differentially expressed genes 
in our CTCs, we detected overexpression of IGF2 (Fig. 3A and STable 2), a gene overexpressed in 20% of early 
HCCs and recently characterized as an HCC epidriver20. Indeed, selective blockade of IGF2 using monoclonal 
antibodies has shown anti-tumoral effects in experimental models of HCC. Notably, IGF2 de-regulation cannot 
be assessed by merely probing the mutation landscape of the tumor, which renders scRNAseq of CTCs an out-
standing tool to detect non-mutated druggable genomic aberrations such as IGF2 overexpression.
In addition to IGF2, many genes were differentially expressed between the two candidate CTCs detected in 
patient 1, as captured by their distribution along PC1. Also, GSEA revealed differences in the top ranked gene sets 
enriched in the 2 candidate CTCs found in this patient, including features suggestive of a more aggressive biolog-
ical behavior in CTC #1 (e.g., E2F targets, G2M checkpoint, KRAS signaling, Fig. 3B). These data are indicative 
of transcriptome heterogeneity in the CTC compartment, and adds credence to our hypothesis that high-density 
expression profiling using scRNAseq could help trace cancer heterogeneity in CTCs. Unfortunately, these patients 
had advanced HCC and were diagnosed using imaging techniques as per clinical practice guidelines, which pre-
vented us to access tumor tissue to recapitulate our findings on CTCs in corresponding tissue. In summary, we 
have applied scRNAseq to identify and characterize CTCs in patients with HCC. Our proof-of-principle study 
demonstrates the advantages of genome-wide transcriptome profiling to confidently detect CTCs, its potential 
role to monitor HCC heterogeneity and its ability to detect HCC driver genes, which will ultimately help custom-
ize therapeutic interventions in these patients.
Experimental Procedures
Human samples, cell sorting and imaging flow cytometry. All patients were enrolled at a single 
institution (Icahn School of Medicine at Mount Sinai (ISMMS)).The study was approved by the ISMMS Program 
for Protection of Human Subjects/Institutional Review Board with protocol number HS-15-00540. All patients 
provided informed consent to participate in this study. All methods were performed in accordance with the 
relevant guidelines and regulations for conducting research in human subjects. Patients were diagnosed with 
hepatocellular carcinoma (HCC) based on the EASL guidelines (3), except one who was enrolled as a control 
subject (i.e., no tumor disease). Blood samples were collected in 8 ml heparin tubes (Vacutainer®, BD Bioscience) 
and processed within 6 hours after collection. Depletion of haematopoietic cells (red cells and CD45-positive 
cells) was performed by an immunodensity assay (Rosette Depletion Kit®, Stem Cells and Ficoll-Paque Plus, 
GE Healthcare). The enriched cell layer at the interphase between plasma and the density medium was collected 
and washed with 2%FBS-PBS for platelet depletion by centrifugation according to the manufacturer. Vital cells 
were counted with a Neubauer haemocytometer and trypan blue staining and resuspended in 2% FBS-PBS. 
To account for red cell contamination, a red cell lysis step was performed (Red cell lysis buffer®, eBioscience). 
One aliquot of 10,000 cells was collected and stored on ice. The remaining cells were stained with the follow-
ing conjugated antibodies ASGPR-1-FITC (sc-52623 FITC; Santacruz Biotech), pan-CK-PE (Clone-C11, 10478; 
Cayman Chemicals), Glypican-3-APC (FAB2119A; R&D systems), EPCAM-VioBlue (CD326(EpCAM)VioBlue; 
Mylteni), CD45-Cy5-PE (PE-Cy™7 Mouse Anti-Human CD45; BD Pharmingen) and analyzed by Imaging Flow 
Cytometry (IFC, Imagestream X Amnis, Millipore) following a similar approach as previously described14. Of the 
twelve channels available, channel 1 was reserved for bright field images, whereas channels 2, 3, 6, 7 and 11 were 
used for the detection of the fluorochromes. Compensation beads were used to provide single color reference 
samples for each fluorochrome. A compensation matrix was built with these reference samples to remove the 
spectral overlap to adjacent channels from each detection channel. CD45-negative cells showing positivity for at 
least 1 marker of our antigen panel (i.e., ASGPR1, pan-CK, GPC3, EPCAM) and with a bright field image allow-
ing the identification of their morphology were defined as potential CTC.
Single cell RNA sequencing. For those samples with potential CTCs based on Imagestream analysis, the sec-
ond aliquot was immediately used for single-cell RNA sequencing (scRNAseq) using Chromium (10X Genomics) 
and Illumina NGS sequencing technologies. The cell density was determined using a C-Chip DHC-N01 dispos-
able hemocytometer. A mixture of 5 μl of 0.04% trypan blue (BioRad) and 5 μl of the single cell suspension was 
loaded onto the hemocytometer and examined at 10X magnification, using the Invitrogen Evos FL Cell Imaging 
System-digital inverted microscope. The single-cell chip loading, Gel bead in Emulsion (GEM) generation & barcod-
ing, post GEM-RT & cDNA amplification, and library construction were performed according to the ChromiumTM 
Single Cell 3′ Protocol - Chemistry v2. For GEM generation an input of 10,000 cells total, at 1,000 cells/uLdensity, was 
targeted for each sample, with a target cell recovery of 6,000 cells. Library construction, enzymatic fragmentation, 
End-repair and A-tailing were performed as follows: pre-cool block at 4 °C hold, fragmentation at 32 °C for 5 min-
utes; End repair and A-tailing 65 °C for 30 minutes and held at 4 °C. Post reaction cleanup was performed, followed 
by adaptor ligation. Adaptor ligation incubation was done at 20 °C for 15 minutes. Post adaptor ligation cleanup was 
then performed, followed by sample index PCR with the following parameters: 98 °C for 45 seconds; followed by 
14 cycles: 98 °C for 20 seconds; 54 °C for 30 seconds; and 72 °C for 20 seconds; followed by 72 °C for 1 minute and 
held at 4 °C. Quantification of the constructed libraries was evaluated using QubitdsDNA HS Assay Kit (Thermo 
Fisher), Agilent cDNA High Sensitivity Kit, and Kapa DNA Quantification Kit for Illumina platforms, following the 
manufacturer’s instructions. Generated libraries were sequenced on the Illumina HiSeq. 2500, using the paired-end 
2 × 125 bp sequencing protocol. Sequencing run parameters were set up according to version 2 chemistry, the num-
ber of cycles for each read as follows: Read 1: 26 cycles, i7 index: 8 cycles, i5 index: 0 cycles and Read 2: 98 cycles.
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Data analyses. We used the package Seurat21 for data analysis using several adjustments to specifically 
increase the sensitivity to outliers. These tuned parameters and filtering involve the consideration of all genes as 
input regardless of the percentage of cells expressing them. No upper-bound limits were enforced when scaling 
the genes. The dataset was analyzed adjusting for the effect of the total amount of expression, or unique molecular 
identifiers (nUMIs), and the percentage of mitochondrial reads by means of linear regression. Subsequently, a 
Principal Component Analysis (PCA) was performed using only the genes identified as highly variable (1,223 
and 1,054 for patient 1 and 2 respectively) for computing the principal components. These highly variable genes 
are selected among those with the highest variation among each of the thirty bins in which the genes are catego-
rized according to their normalized strength of expression. No lower limits regarding strength of expression were 
imposed in order to capture the variation derived from the subtle expression signal of CTCs. Subsequently, we 
visualized this data in a two-dimensional PCA space to identify the outliers. The marker genes for these candidate 
CTCs were manually curated, and GSEA was run on scaled fold-changes of each CTC vs. all others cells. The 
loadings of the principal component (PC) 1 rank the genes that more accurately discriminate all the elements 
along this PC. As a proxy for expression differences in individual CTCs versus non tumoral cells, and given the 
limitations for differential expression testing in individual samples (dropout and lack of replicates to estimate 
variance), we used the residuals of expression after normalization (i.e., scaling, centering) and regression.
For the analysis of the rest of the blood cells we used a robust method with upper-limit scaling followed by 
the linear regression of the undesired effect of nUMIs and percentage of mitochondrial reads. This analysis was 
less contingent on outlier detection, so we followed a conventional approach using non-linear clustering, filter-
ing out those genes which are expressed in less than 5 cells, and capping scaled maximum expression. Next, we 
performed dimensionality reduction with PCA on all genes, and later we clustered the cells with a graph-based 
algorithm for modularity optimization on principal component space. We added to this robust clustering method 
the supervised labeling of the outliers identified by the outlier-focused analysis (i.e., the CTCs. See above). After 
this, we computed marker genes22 for the blood cell clusters modules (not CTCs). Subsequently we applied man-
ifold learning techniques (non-linear dimensionality reduction) to gain insight on the structure of the data and 
clusters. In particular, we used tSNE23 on PC space and used it to visualize the clusters in the blood.
In order to gain power to calculate marker genes for each cluster, we performed a combined analysis of the two 
single cell datasets of both patients. For the combined analysis, we selected the union of the top 2,000 genes with 
the highest dispersion (variance to mean ratio) from both datasets. We then ran a canonical correlation analysis 
(CCA) to identify common sources of variation between the two datasets. The result is, effectively, a form of 
dimensionality reduction, where 20 canonical vectors were calculated. The distributions of the cells’ embeddings 
for these canonical vectors were aligned in order to remove batch effects (i.e. aligning the CCA subspaces). Next, 
on the combined dataset, we ran maker selection algorithms; first using Area Under the ROC Curve to rank the 
genes with most predictive power for each cluster. We used as well a bimodal (discrete and continuous) test22 for 
single cell differential expression. Analyses were performed using R and raw sequencing data are deposited in 
NCBI’s Gene Expression Omnibus under accession number GSE107747.
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